Large-scale production of rotavirus VLP as vaccine candidate using Baculovirus Expression Vector System (BEVS)

被引:0
|
作者
Park, JY
Kim, H
Hwang, HK
Lee, SJ
Kim, HS
Hur, BK
Ryu, YW
An, CN
Kim, JS
机构
[1] GreenCross Vaccine Corp, Vaccine Res Inst, Yongin 449903, South Korea
[2] Ajou Univ, Dept Mol Sci & Technol, Suwon 442749, South Korea
[3] Inha Univ, Dept Biotechnol & Bioengn, Inchon 402751, South Korea
关键词
rotavirus; virus-like particle; Baculovirus Expression Vector System; vaccine; SJ9 insect cell;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Rotavirus virus-like particle (VLP) composed of VP2, VP6, and VP7 was expressed in the Baculovirus Expression Vector System (BEVS). Sf9 cell, a host of the baculovirus, was cultured from a 0.5-1 spinner flask to the 50-1 bioreactor system. Sf9 cell was maintained at cell density between 3.0E+05 and 3.0E+06 cells/ml and grew up to 1.12E+07 cells/ml in the bioreactor. Growth kinetics was compared under different culture systems and showed similar growth kinetics with 20.1-25.2 h of doubling time. Early exponentially growing cell culture was infected with three recombinant baculoviruses expressing VP2, VP6, and VP7 protein at 1.0, 2.0, and 0.2 moi, respectively. The expression of rotavirus proteins was confirmed by Western blot analysis and its three-layered virus-like structure was observed under an electron microscope. Rotavirus VLP was semipurified and immunized in ICR mice intramuscularly. Rotavirus-specific serum antibody was detected from 2 weeks after the immunization and lasted at least 21 weeks of the post-immunization, indicating its possible use as a vaccine candidate.
引用
收藏
页码:35 / 40
页数:6
相关论文
共 50 条
  • [1] Large-scale production of pharmaceutical proteins using the baculovirus expression vector system (BEVS).
    Persson, B
    Hansen, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U292 - U292
  • [2] Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development
    Hong, Qiaonan
    Liu, Jian
    Wei, Yuquan
    Wei, Xiawei
    VACCINES, 2023, 11 (07)
  • [3] Process development for pandemic influenza VLP vaccine production using a baculovirus expression system
    Chia-Chun Lai
    Yu-Chieh Cheng
    Pin-Wen Chen
    Ting-Hui Lin
    Tsai-Teng Tzeng
    Chia-Chun Lu
    Min-Shi Lee
    Alan Yung-Chih Hu
    Journal of Biological Engineering, 13
  • [4] Process development for pandemic influenza VLP vaccine production using a baculovirus expression system
    Lai, Chia-Chun
    Cheng, Yu-Chieh
    Chen, Pin-Wen
    Lin, Ting-Hui
    Tzeng, Tsai-Teng
    Lu, Chia-Chun
    Lee, Min-Shi
    Hu, Alan Yung-Chih
    JOURNAL OF BIOLOGICAL ENGINEERING, 2019, 13 (01)
  • [5] Adaptation of baculovirus system for large-scale production of rAAV vector serotypes
    Kohlbrenner, E
    Aslanidi, G
    Knop, DR
    Gorbatyuk, O
    Nash, K
    Mandel, RJ
    Muzyczka, N
    Burns, BJ
    Snyder, RO
    Zolotukhin, S
    MOLECULAR THERAPY, 2004, 9 : S161 - S161
  • [6] Expression and Production of Human Interleukin-7 in Insect Cells Using Baculovirus Expression Vector System (BEVS)
    Maryam Mirzaei
    Barbara Jardin
    Cynthia B. Elias
    Satya Prakash
    Applied Biochemistry and Biotechnology, 2008, 151 : 93 - 103
  • [7] Expression and production of human interleukin-7 in insect cells using baculovirus expression vector system (BEVS)
    Mirzaei, Maryam
    Jardin, Barbara
    Elias, Cynthia B.
    Prakash, Satya
    APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2008, 151 (01) : 93 - 103
  • [8] Production of hevein, a major latex allergen, as avidin fusion protein using a baculovirus expression vector system (BEVS)
    Airenne, KJ
    Laitinen, OH
    Alenius, H
    Mikkola, J
    Kalkkinen, N
    Yeang, HY
    Sitiarija, M
    Turijanmaa, K
    Palosuo, T
    Kulomaa, MS
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (01) : S79 - S79
  • [9] Optimization of genetic code expansion in the baculovirus expression vector system (BEVS)
    Cronin, Ciaran N.
    PROTEIN EXPRESSION AND PURIFICATION, 2023, 210
  • [10] Platform development for AAV manufacturing with the Baculovirus Expression Vector System (BEVS)
    Garza, Z. Felix
    Schippers, K.
    Varghese, F. S.
    van de Waterbeemd, B.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A110 - A110